Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor (MUCOLIMEX)

University Hospital, Lille

Status: Not yet enrolling

Conditions: Mucoviscidosis; Cystic Fibrosis (CF)

Treatments: Device: Measurement of resistance through forced oscillations and continuous measurement of ventilation and inspiratory capacity during TM6

Study type: Interventional

Funder types: Other

Identifiers

NCT07314229

2024-A02709-38 (Registry Identifier)

2024_0277

Details and patient eligibility

About

Cystic fibrosis is a genetic disorder affecting the entire body and associated with respiratory exacerbations, impaired quality of life and reduced life expectancy. The therapeutic management of cystic fibrosis has been profoundly changed by the recent arrival of a combination of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Elexacaftor-Tezacaftor-Ivacaftor (ETI), which improve quality of life, respiratory function and reducing the number of exacerbations. The impact of these treatments on exercise adaptation has not been clearly identified.

The main objective is to estimate the prevalence of ventilatory reserve amputation during submaximal exercise testing assessed by the 6-minute walk test (6MWT) in patients with cystic fibrosis treated with ETIs.

Full description

Cystic fibrosis is a genetic disorder affecting the entire body and associated with respiratory exacerbations, impaired quality of life and reduced life expectancy. The therapeutic management of cystic fibrosis has been profoundly changed by the recent arrival of a combination of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators, Elexacaftor-Tezacaftor-Ivacaftor (ETI), which improve quality of life, respiratory function and reducing the number of exacerbations. The impact of these treatments on exercise adaptation has not been clearly identified.

The main objective is to estimate the prevalence of ventilatory reserve amputation during submaximal exercise testing assessed by the 6-minute walk test (6MWT) in patients with cystic fibrosis treated with ETIs.

Enrollment: 130 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female
• Adult aged 18 or over
• Suffering from cystic fibrosis
• Treated at the CRCM in Lille and Créteil
• Treated by ETI
• Be covered by social security
• Be able to understand the requirements of the study, provide written informed consent, and comply with the study's data collection procedures

Exclusion criteria

• Medical contraindication or inability to perform a stress test according to ERS recommendations

  • Absolute contraindications
  • Relative contraindications:

• Exacerbation of the condition in the 4 weeks preceding the V1 visit (27).

• Pregnant or breastfeeding women

• Administrative reasons

• Persons deprived of their liberty

• Minors or protected adults

• Persons who have refused or are unable to give informed consent

• Persons in emergency situations

Trial design

Primary purpose: Health Services Research

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

130 participants in 1 patient group

patients treated with ETI (Kaftrio-Kalydeco©)

Experimental group

Treatment:

Device: Measurement of resistance through forced oscillations and continuous measurement of ventilation and inspiratory capacity during TM6